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Introduction

Case Report (Cont.)

• Vascular Thromboembolism (VTE) is seen with
hypercoagulable state and it can be a reason of
significant morbidity and mortality.
• Cancer is considered as one of the most common
causes of hypercoagulability and developing VTE.
• Since novel oral anticoagulants (NOACs) have
been introduced in market for VTE prophylaxis
and treatment, their use have been increased
significantly as they are easy to use without
episodic monitoring.
• Rivaroxaban is one of the commonly used
NOACs and some of the studies have shown its
good efficacy for VTE.

• Vascular surgery was consulted and they put the
patient on heparin drip. CTA Aorta with run off
was ordered to find out source of VTE.
• Unfortunately, CT report showed pancreatic head
cancer with metastasis to liver, adrenals and
lumber vertebrae which was definitively
diagnosed as “Primary Pancreatic
Adenocarcinoma” on biopsy.
• Oncology was consulted and they recommended
higher dose of Rivaroxaban 15 mg PO BID on
discharge. Still patient came back to ED with
worsening of symptoms and pain in both feet due
to VTE exacerbation.
• Patient was then switched to fondaparinux and it
helped her from keep getting recurrent VTE
exacerbation.

Case Report
• 71 year old female with PMH of persistent A-fib on
Rivaroxaban, pulmonary hypertension, HTN, DM2 presented to the ED with severe pain in both
feet.
• On physical examination, they seemed ischemic
with splotchy cyanotic/pallor discoloration on
multiple toes of both feet.
• Patient was already on 20 mg PO daily dose of
Rivaroxaban for A-fib which is also prophylactic
dose for VTE.
• Her fibrinogen and D-dimer were elevated at 185
and >5000 respectively.

Imaging
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Results
• Traditionally, warfarin and enoxaparin have been
used as first-line agents for VTE treatment.
• Their efficacy have been proven with acceptable
risks of bleeding. As enoxaparin needs to be
injected and warfarin requires regular monitoring
of INR, patients were not compliant with using
them.
• Conversely, NOACs can provide innocuous and
more compliant alternative to warfarin and
enoxaparin.
• Rivaroxaban has been most commonly used
NOAC for this purpose and some of the studies
bolsters its efficacy for VTE.
• Nonetheless, few case reports are out that don’t
support Rivaroxaban’s effectiveness as a
prophylactic agent for preventing VTE.

Conclusion
• We propose that it still requires more postmarketing research in assessing Rivaroxaban’s
real efficacy/effectiveness as a prophylactic agent
for VTE in Pancreatic as well as other cancers.
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